Literature DB >> 2924890

Isolation and characterization of a tumor necrosis factor binding protein from urine.

I Olsson1, M Lantz, E Nilsson, C Peetre, H Thysell, A Grubb, G Adolf.   

Abstract

Tumor necrosis factor (TNF)/cachectin can produce both beneficial and harmful manifestations. Mechanisms may operate to counteract potentially harmful effects such as shock and cachexia. The TNF binding protein (TNF-BP), which is found at increased levels in serum and urine of patients with chronic renal failure, may play such a role. TNF-BP was purified 1,000,000-fold to homogeneity from urine of patients with chronic renal failure by use of ion exchange chromatography, affinity chromatography on TNF-Sepharose and reverse phase chromatography. The purified protein contained only one chain with an apparent Mr on sodium dodecyl sulfate-polyacrylamide gel electrophoresis of 30,000. The aminoterminal amino acid sequence D-S-V-X-P-Q-G-K-Y-I-H-P-Q-V-N-S-I-X-K-T revealed no significant homologies with previously described protein sequences. TNF-BP may act as a regulator of the bioactivities of TNF/cachectin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2924890     DOI: 10.1111/j.1600-0609.1989.tb00111.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  44 in total

Review 1.  The role of anti-cytokine therapy in the failing heart.

Authors:  A Deswal; A Misra; B Bozkurt
Journal:  Heart Fail Rev       Date:  2001-03       Impact factor: 4.214

2.  Delivery of soluble tumor necrosis factor receptor from in-situ forming PLGA implants: in-vivo.

Authors:  R E Eliaz; D Wallach; J Kost
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

Review 3.  Cytokines, receptors, and inhibitors.

Authors:  G Gehr; T Braun; W Lesslauer
Journal:  Clin Investig       Date:  1992-01

4.  Elevated TNF receptor plasma concentrations in patients with rheumatoid arthritis.

Authors:  B Heilig; M Wermann; H Gallati; M Brockhaus; B Berke; O Egen; A Pezzutto; W Hunstein
Journal:  Clin Investig       Date:  1992-01

5.  Regulation of the release of tumour necrosis factor (TNF)alpha and soluble TNF receptor by gamma irradiation and interferon gamma in Ewing's sarcoma/peripheral primitive neuroectodermal tumour cells.

Authors:  F van Valen; V Kentrup-Lardong; B Truckenbrod; C Rübe; W Winkelmann; W W Jürgens
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

6.  Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor.

Authors:  R G Goodwin; D Anderson; R Jerzy; T Davis; C I Brannan; N G Copeland; N A Jenkins; C A Smith
Journal:  Mol Cell Biol       Date:  1991-06       Impact factor: 4.272

7.  Molecular cloning and expression of the mouse Tnf receptor type b.

Authors:  J G Rothe; M Brockhaus; R Gentz; W Lesslauer
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

8.  A radioreceptor assay for TNF alpha-binding proteins.

Authors:  V Miller; K D Muirden
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

9.  Multifaceted inhibition of anti-tumour immune mechanisms by soluble tumour necrosis factor receptor type I.

Authors:  C L Selinsky; K L Boroughs; W A Halsey; M D Howell
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

10.  Relationship between soluble tumor necrosis factor (TNF) receptors and TNF alpha during immunotherapy with interleukin-2 and/or interferon alpha.

Authors:  R Landmann; U Keilholz; C Scheibenbogen; M Brockhaus; H Gallati; H Denz; M Bargetzi; C Ludwig
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.